

## DAFTAR PUSTAKA

1. Topal E, Aydemir K, Caglar O, Arda B, Kayabasi O, Yildiz M, et al. Fatty Liver Disease : Diagnosis and Treatment. *Int J Clin Exp Med Sci.* 2021;2:343–357.
2. Setiati S, Alwi I, Sudoyo A, Stiyohadi B. *Buku Ajar Ilmu Penyakit Dalam.* VI. Jakarta: Interna Publishing; 2014. 2316–2318 p.
3. Seitz HK, Bataller R, Cortez-Pinto H, Gao B, Gual A, Lackner C, et al. Alcoholic liver disease. *Nat Rev Dis Primers.* 2018;4:1–22.
4. Dennis K, Stephen H, Jameson L, Fauci A, Longo D, Loscalzo J. *Harrison - Principles of Internal Medicine 19th.* 19th ed. Singapore: McGraw; 2015. 2052–2057 p.
5. Ravertio D, Subroto T, Mariadi IK, Somayana G, Dwipayana IMP. Gambaran Perlemakan Hati Non-Alkoholik di RSUP Sanglah Denpasar Periode Tahun 2017-2018. *E-Jurnal Medika.* 2019;8:1–3.
6. Sharma V, Juglan KC. Ultrasound-based Classification of Fatty Liver Disease: A Review. *J Phys Conf Ser.* 2020;1531:1–10.
7. Yoshimura Y, Hamaguchi M, Hashimoto Y, Okamura T, Nakanishi N, Obora A, et al. Obesity and metabolic abnormalities as risks of alcoholic fatty liver in men: NAGALA study. *BMC Gastroenterol.* 2021;21:1–9.
8. Zhang P, Wang W, Mao M, Gao R, Shi W, Li D, et al. Similarities and Differences: A Comparative Review of the Molecular Mechanisms and Effectors of NAFLD and AFLD. *Front Physiol.* 2021;12:1–14.
9. Sun FR, Wang BY. Alcohol and metabolic-associated fatty liver disease. *J Clin Transl Hepatol.* 2021;9:719–730.
10. Rachmatullah TF, Permatadewi CO, Hutami HT, Limantoro C, Purnomo MD. Correlation between Non-Alcoholic Fatty Liver Disease (NAFLD) fibrosis score (NFS) with Left Ventricular Mass Index (LVMI) in patients with NAFLD. *BioMed Res Int.* 2021;7:79–85.

11. Yoneda M, Yamamoto T, Honda Y, Imajo K, Ogawa Y, Kessoku T, et al. Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan. *J Gastroenterol*. 2021;56:1022–1032.
12. Cho EJ, Jung GC, Kwak MS, Yang JI, Yim JY, Yu SJ, et al. Fatty liver index for predicting nonalcoholic fatty liver disease in an asymptomatic korean population. *Diagnostics*. 2021;11:1–8.
13. Bharath R, Mishra PK, Rajalakshmi P. Automated quantification of ultrasonic fatty liver texture based on curvelet transform and SVD. *Biocybern Biomed Eng*. 2018;38:145–157.
14. Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The Diagnosis and Management of Nonalcoholic Fatty Liver Disease: Practice Guidance From the American Association for the Study of Liver Diseases. *Hepatology Practice Guidance*. 2017;67:328–358.
15. Murag S, Ahmed A, Kim D. Recent Epidemiology of Nonalcoholic Fatty Liver Disease. *Gut Liver*. 2021;15:206–216.
16. Marchisello S, di Pino A, Scicali R, Urbano F, Piro S, Purrello F, et al. Pathophysiological, molecular and therapeutic issues of nonalcoholic fatty liver disease: An overview. *Int J Mol Sci*. 2019;20:1–33.
17. Chang Y, Cho YK, Cho J, Jung HS, Yun KE, Ahn J, et al. Alcoholic and Nonalcoholic Fatty Liver Disease and Liver-Related Mortality: A Cohort Study. *Am J Physiol Gastrointest Liver Physiol*. 2019;114:620–629.
18. Setiono DD, Wantania FEN, Polii EBI. Risk Factors of Non-Alcoholic Fatty Liver Disease in Adults. *e-CliniC*. 2022;10:234-239.
19. Idalsoaga F, Kulkarni A v., Mousa OY, Arrese M, Arab JP. Non-alcoholic Fatty Liver Disease and Alcohol-Related Liver Disease: Two Intertwined Entities. *Front Med (Lausanne)*. 2020;7:1–17.
20. Imanuel Setiawan S, Kurniawan J, Bhakti Asih R, Tangerang K, Hepatobilier D. Pilihan Tatalaksana Penyakit Perlemakan Hati Non-

- Alkohol (Non-Alcoholic Fatty Liver Disease/ NAFLD). *CDK* 3. 2021;48:173–175.
21. Li J, Zou B, Yeo YH, Feng Y, Xie X, Lee DH, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999–2019: a systematic review and meta-analysis. *Lancet Gastroenterol Hepatol*. 2019;4:389–398.
  22. Godoy-Matos AF, Silva Júnior WS, Valerio CM. NAFLD as a continuum: From obesity to metabolic syndrome and diabetes. *Diabetol Metab Syndr*. 2020;12:1–20.
  23. Tilg H, Adolph TE, Moschen AR. Multiple Parallel Hits Hypothesis in Nonalcoholic Fatty Liver Disease: Revisited After a Decade. *Hepatology*. 2021;73:833–842.
  24. Fang YL, Chen H, Wang CL, Liang L. Pathogenesis of non-alcoholic fatty liver disease in children and adolescence: From “two hit theory” to multiple hit model". *World J Gastroenterol*. 2018;24:2974–2983.
  25. Pappachan JM, Babu S, Krishnan B, Ravindran NC. Non-alcoholic fatty liver disease: A clinical update. *J Clin Transl Hepatol*. 2017;5:384–393.
  26. Huang T, Behary J, Zekry A. Non-alcoholic fatty liver disease: a review of epidemiology, risk factors, diagnosis and management. *Intern Med J*. 2020;50:1038–1047.
  27. Dharmalingam M, Yamasandhi Pg. Nonalcoholic fatty liver disease and Type 2 diabetes mellitus. *Indian J Endocrinol Metab*. 2018;22:421–428.
  28. Joseph W, George N, Prasannarajan A, Kannan A. Case-control study evaluating relationship of blood pressure and anthropometric parameters with non-alcoholic fatty liver disease. *Natl J Physiol Pharm Pharmacol*. 2018;8:1128–1134.
  29. Yetti H, Prahastiwi NU, Susanti R, Decroli E, Miro S. Characteristics of Non-Alcoholic Fatty Liver Disease Patients at Dr. M. Djamil General Hospital Padang. *Indones j gastroenterol hepatol dig endosc*. 2020;21:171–176.

30. Deng J, Zhang Y, Bu L, Shi H, Tang H, Wang S, et al. The Prevalence, Popular Trends, and Associated and Predictive Factors of Non-Obese Fatty Liver Disease. *Front Endocrinol (Lausanne)*. 2021;12:1–7.
31. Kim D, Konyn P, Sandhu KK, Dennis BB, Cheung AC, Ahmed A. Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States. *J Hepatol*. 2021;75:1284–1291.
32. Hu XY, Li Y, Li LQ, Zheng Y, Lv JH, Huang SC, et al. Risk factors and biomarkers of non-alcoholic fatty liver disease: An observational cross-sectional population survey. *BMJ Open*. 2018;8:1–7.
33. Ananth V, Priyadharsini RP, Subramanian U. Pathogenesis, Diagnosis, and Management of Metabolic Syndrome: A Comprehensive Review. *SBV Journal of Basic, Clinical and Applied Health Science*. 2021;4:39–45.
34. Antunes C, Azadfar M, Hollat G. Fatty Liver. *StatPearls*; 2021.
35. Muthiah MD, Cheng Han N, Sanyal AJ. A clinical overview of non-alcoholic fatty liver disease: A guide to diagnosis, the clinical features, and complications—What the non-specialist needs to know. *Diabetes Obes Metab*. 2022;24:3–14.
36. Khoonsari M, Mohammad M, Azar H, Ghavam R, Hatami K, Asobar M, et al. Clinical Manifestations and Diagnosis of Nonalcoholic Fatty Liver Disease. *Iran J Pathol*. 2017;12:99–105.
37. Muthiah MD, Cheng Han N, Sanyal AJ. A clinical overview of non-alcoholic fatty liver disease: A guide to diagnosis, the clinical features, and complications—What the non-specialist needs to know. *Diabetes Obes Metab*. 2022;24:3–14.
38. Hassan Z, Latief M, Ramzan M, Abbas F, Farooq S. Metabolic Syndrome in Adults with Nonalcoholic Fatty Liver Disease. *JRENHEP*. 2021;5:34–37.
39. Fahed G, Aoun L, Zerdan MB, Allam S, Zerdan MB, Bouferraa Y, et al. Metabolic Syndrome: Updates on Pathophysiology and Management in 2021. *Int J Mol Sci*. 2022;23:1–38.

40. Rochlani Y, Pothineni NV, Kovelamudi S, Mehta JL. Metabolic syndrome: Pathophysiology, management, and modulation by natural compounds. *Ther Adv Cardiovasc Dis*. 2017;11:215–225.
41. Sheela J, Kannan L, V J. A Hospital Based Case Control Study To Find Out The Risk Factors For Fatty Liver And Non Fatty Liver Patients Admitted In Tertiary Care Hospital, Chennai. *Indian J. Med. Res*. 2018;7:71–73.
42. Bandaru VCSS, Chaudhury JR, Lalitha P, Reddy SN, Misra PK, Balaraju B, et al. Prevalence of asymptomatic nonalcoholic fatty liver disease in nondiabetic participants: a study from south india. *Egypt J Intern Med*. 2019;31:92–98.
43. Caballería L, Pera G, Auladell MA, Torán P, Muñoz L, Miranda D, et al. Prevalence and factors associated with the presence of nonalcoholic fatty liver disease in an adult population in Spain. *Eur J Gastroenterol Hepatol*. 2010;22:24–32.
44. Alam S, Fahim SM, Chowdhury MAB, Hassan MZ, Azam G, Mustafa G, et al. Prevalence and risk factors of non-alcoholic fatty liver disease in Bangladesh. *JGH Open*. 2018;2:39–46.
45. Amarapurkar D, Kamani P, Patel N, Gupte P, Kumar P, Agal S, et al. Prevalence of non-alcoholic fatty liver disease: population based study. *Ann Hepatol*. 2007;6:161–163.
46. Chandran P, George R. Association of Level of Physical Activity, Diet and Lipid Profile with Non-alcoholic Fatty Liver Disease - A Case Control Study. *Indian J Physiol Pharmacol*. 2019;63:203–210.
47. Goh SC, Ho ELM, Goh KL. Prevalence and risk factors of non-alcoholic fatty liver disease in a multiracial suburban Asian population in Malaysia. *Hepatol Int*. 2013;7:548–554.
48. Amirkalali B, Poustchi H, Keyvani H, Reza KHANSARI M, Ajdarkosh H, Maadi M, et al. Prevalence of Non-Alcoholic Fatty Liver Disease and Its Predictors in North of Iran. *Iranian J Publ Health [Internet]*. 2014;43:1275–1283. Available from: <http://ijph.tums.ac.ir>

49. Pinidiyapathirage M, Dassanayake AS, Rajindrajith S, Kalubowila U, Kato N, Wickremasinghe A, et al. Non-alcoholic fatty liver disease in a rural, physically active, low income population in Sri Lanka. *BMC Res Notes*. 2011;4:1–5.
50. Dassanayake AS, Kasturiratne A, Rajindrajith S, Kalubowila U, Chakrawarthy S, de Silva AP, et al. Prevalence and risk factors for non-alcoholic fatty liver disease among adults in an urban Sri Lankan population. *J Gastroenterol Hepatol*. 2009;24:1284–1288.
51. Oikonomou D, Georgiopoulos G, Katsi V, Kourek C, Tsioufis C, Alexopoulou A, et al. Non-alcoholic fatty liver disease and hypertension: Coprevalent or correlated?. *Eur J Gastroenterol Hepatol*. 2018;30:979–985.
52. Li Y, Wang J, Tang Y, Han X, Liu B, Hu H, et al. Bidirectional association between nonalcoholic fatty liver disease and type 2 diabetes in Chinese population: Evidence from the Dongfeng-Tongji cohort study. *PLoS One*. 2017;12:1–16.

